Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New toolkit aims to boost PrEP access for youth in alabama and botswana

NCT ID NCT07597824

Prevention Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 4 times

Summary

This study looks at how to make HIV prevention pills (PrEP) easier for young people to get and keep using. Researchers will follow 1000 current or eligible PrEP users in Alabama and Botswana for 2 years. They will also create and test a decision-support toolkit to help patients and doctors talk about PrEP. The goal is to improve access and reduce HIV infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could make it easier for young people to get and stay on PrEP, reducing HIV infections in these communities.
What could go wrong
This is an observational study, not a treatment trial. The toolkit may not work as hoped, and results may not apply to other regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Current PrEP users, providers or clinic administrators, and policy makers or program leaders related to PrEP usage in AL and Botswana

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Group 1 * Inclusion for Alabama site: * 18 years of age or older * Currently using or eligible for PrEP * Inclusion for Botswana site: * 18 years of age or older * Participated in the parent Tshireletso study in Botswana * Exclusion for both sites: * Under the age of 18 * HIV positive Group 2 * Inclusion for both sites: * 18 years of age or older * Currently working as PrEP providers or clinic administrators at outpatient clinics * Exclusion for both sites: * Under the age of 18 Group 3 * Inclusion for both sites: * 18 years of age or older * Currently working as policy makers or program leaders at outpatient clinics * Exclusion for both sites: * Under the age of 18

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contraception are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contraception HIV infections PREP

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Princess Marina Hospital

    Bontleng, Gaborone, Botswana

More trials for these conditions

Other studies related to the condition(s) this trial covers.